Literature DB >> 17010810

Activation of apoptotic caspase cascade during the transition to pressure overload-induced heart failure.

Narain Moorjani1, Manzoor Ahmad, Pedro Catarino, Robin Brittin, Danyah Trabzuni, Futwan Al-Mohanna, Navneet Narula, Jagat Narula, Stephen Westaby.   

Abstract

OBJECTIVES: A pressure overload model was developed to simulate aortic stenosis and assess caspase activity during the transition to heart failure.
BACKGROUND: Cardiomyocyte apoptosis is implicated in the pathogenesis of heart failure, and caspase activation is central to this pathophysiological process.
METHODS: A total of 10 sheep were banded with variable aortic constriction devices, progressively inflated to increase left ventricular (LV) afterload. Serial LV endomyocardial biopsy samples were obtained to measure caspase activity and presence of apoptosis.
RESULTS: Over the first 3 to 4 weeks, hypertrophy developed in the sheep (LV mass index 90.8 +/- 4.9 g/m2 vs. 44.0 +/- 3.0 g/m2, p < 0.01), followed by gradual dilatation of the left ventricle (diastolic LV internal diameter 4.23 +/- 0.08 cm vs. 3.39 +/- 0.07 cm, p < 0.01). Ventricular function remained stable until 7 to 8 weeks after banding, when there was significant deterioration (fractional shortening 18.3 +/- 2.4% vs. 46.9 +/- 2.6%, p < 0.01), associated with clinical heart failure. Serial LV endomyocardial biopsy samples were obtained at each echocardiographically defined stage (LV hypertrophy, LV dilation, and LV failure). Activity of caspases-3, -8, and -9 (measured by specific fluorogenic peptide substrates and immunohistochemistry) increased progressively, particularly with the onset of myocardial dysfunction (caspase-3 7.92 +/- 1.19 vs. 1.00 +/- 0.15, caspase-8 1.94 +/- 0.21 vs. 1.00 +/- 0.04, caspase-9 5.87 +/- 0.97 vs. 1.00 +/- 0.18 relative fluorescent units, p < 0.05). No evidence of deoxyribonucleic acid (DNA) fragmentation, however, was identified by immunohistochemical assays.
CONCLUSIONS: Activation of cardiomyocyte caspase enzymes occurs during the transition to heart failure, without completion of apoptotic DNA fragmentation. Increased activity of caspase-8 and -9 suggests both mitochondrial and death-receptor mediated pathways are involved in this pathological process. Further knowledge of these pathways may stimulate development of apoptosis-based strategies for slowing progression of heart failure in aortic stenosis patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010810     DOI: 10.1016/j.jacc.2006.05.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting ROS-TNF-α-caspase signaling pathway.

Authors:  Xiu-xiu Lv; Xiao-hui Yu; Hua-dong Wang; Yu-xia Yan; Yan-ping Wang; Da-Xiang Lu; Ren-Bin Qi; Chao-Feng Hu; Hong-Mei Li
Journal:  Chin J Integr Med       Date:  2012-02-29       Impact factor: 1.978

2.  Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature.

Authors:  William M Yarbrough; Rupak Mukherjee; Robert E Stroud; William T Rivers; J Marshall Oelsen; Jennifer A Dixon; Shaina R Eckhouse; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-04       Impact factor: 5.209

Review 3.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.

Authors:  William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

4.  Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload.

Authors:  Misun Park; Stephen F Vatner; Lin Yan; Shumin Gao; Seunghun Yoon; Grace Jung Ah Lee; Lai-Hua Xie; Richard N Kitsis; Dorothy E Vatner
Journal:  Basic Res Cardiol       Date:  2013-01-01       Impact factor: 17.165

5.  Apoptosis in severe, compensated pressure overload predominates in nonmyocytes and is related to the hypertrophy but not function.

Authors:  Ricardo J Gelpi; Misun Park; Shumin Gao; Sunil Dhar; Dorothy E Vatner; Stephen F Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-10       Impact factor: 4.733

6.  Nicotine plus a high-fat diet triggers cardiomyocyte apoptosis.

Authors:  Indrani Sinha-Hikim; Theodore C Friedman; Mark Falz; Victor Chalfant; Mohammad Kamrul Hasan; Jorge Espinoza-Derout; Desean L Lee; Carl Sims; Peter Tran; Sushil K Mahata; Amiya P Sinha-Hikim
Journal:  Cell Tissue Res       Date:  2016-12-05       Impact factor: 5.249

7.  Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy.

Authors:  Elena Westphal; Susanne Rohrbach; Michael Buerke; Hagen Behr; Dorothea Darmer; Rolf-Edgar Silber; Karl Werdan; Harald Loppnow
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

8.  Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium.

Authors:  Yeong-Hoon Choi; Douglas B Cowan; Adrian M Moran; Steven D Colan; Christof Stamm; Koh Takeuchi; Ingeborg Friehs; Pedro J del Nido; Francis X McGowan
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-17       Impact factor: 5.209

9.  CaMKIIδB mediates aberrant NCX1 expression and the imbalance of NCX1/SERCA in transverse aortic constriction-induced failing heart.

Authors:  Ying-Mei Lu; Jiyun Huang; Norifumi Shioda; Kohji Fukunaga; Yasufumi Shirasaki; Xiao-Ming Li; Feng Han
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

10.  A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells.

Authors:  Saiyang Zhang; Tingyu Li; Li Zhang; Xiangyu Wang; Hangqi Dong; Lili Li; Dongjun Fu; Yongchun Li; Xiaolin Zi; Hong-Min Liu; Yanbing Zhang; Hongde Xu; Cheng-Yun Jin
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.